Dr. Schroeder most recently served as a director at AGC Biologics, formerly CMC Biologics, a global contract development and manufacturing organization (CDMO), where he participated in the commercial launch of multiple products. In that role, he supported more than 25 client projects as they progressed toward first-in-human clinical trials, commercial product launch and ongoing commercial supply. These efforts included creative resolution of complex challenges related to commercial processes that directly impacted a range of regulatory interactions and filings. In directing AGC's purification development team, Dr. Schroeder oversaw early-to-late phase development, process characterization, process control strategy, commercial process support and technology transfer/facility fit activities.
Dr. Schroeder earned his Ph.D. in biochemical engineering and his master of science in molecular biotechnology from Bielefeld University in Bielefeld, Germany. He has previously served as a visiting scientist for protein purification at Rensselaer Polytechnic Institute and a visiting scientist for cell culture engineering at the University of Minnesota.
"As we continue to strategically increase our focus on process development to best align with industry needs, we have prioritized supplementing our in-house process science talent. With Magnus joining our team as vice president of process sciences, we have significantly strengthened the company's expertise in this critical area, positioning us to continue to deliver our customers industry-leading service and results," said Roger Lias, president and chief executive officer, Avid. "Importantly, we believe that the innovative process development insights and approaches that Magnus is bringing to Avid will further support our new customer acquisition efforts by highlighting additional unique competitive advantages that we can offer companies with biopharmaceutical development and manufacturing needs."